T. Rowe Price Investment Management
ALNY icon

T. Rowe Price Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

T. Rowe Price Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.7B Buy
5,642,173
+448,849
+9% +$135M 1.11% 16
2026
Q1 		$1.72B Buy
5,193,324
+3,439,684
+196% +$1.17B 1.18% 13
2025
Q4 		$697M Sell
1,753,640
-420,344
-19% -$186M 0.44% 57
2025
Q3 		$991M Sell
2,173,984
-2,107,295
-49% -$858M 0.61% 36
2025
Q2 		$1.4B Sell
4,281,279
-136,866
-3% -$37.9M 0.88% 20
2025
Q1 		$1.19B Buy
4,418,145
+33,696
+0.8% +$8.66M 0.79% 22
2024
Q4 		$1.03B Buy
4,384,449
+1,245,195
+40% +$327M 0.64% 40
2024
Q3 		$863M Sell
3,139,254
-14,373
-0.5% -$3.74M 0.52% 57
2024
Q2 		$766M Buy
3,153,627
+280,723
+10% +$44.3M 0.48% 64
2024
Q1 		$429M Sell
2,872,904
-553,159
-16% -$92.3M 0.26% 102
2023
Q4 		$656M Buy
3,426,063
+27,204
+0.8% +$4.63M 0.43% 74
2023
Q3 		$602M Buy
3,398,859
+161,235
+5% +$30.8M 0.43% 67
2023
Q2 		$615M Buy
3,237,624
+206,803
+7% +$41M 0.42% 68
2023
Q1 		$607M Sell
3,030,821
-171,972
-5% -$36.1M 0.44% 59
2022
Q4 		$761M Buy
3,202,793
+10,609
+0.3% +$2.26M 0.58% 44
2022
Q3 		$639M Buy
+3,192,184
New +$609M 0.51% 54

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Investment Management's ALNY Position: Q2 2026 in Review

T. Rowe Price Investment Management increased its Alnylam Pharmaceuticals (ALNY) stake by 8.6% in Q2 2026, buying an estimated $135M and bringing the position to 5,642,173 shares worth $1.7B. The position accounts for 1.11% of the portfolio, ranked #16.

T. Rowe Price Investment Management first reported a position in ALNY in Q3 2022 and has held it in 16 quarters since. The position peaked at $1.72B in Q1 2026. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • T. Rowe Price Investment Management held 5,642,173 shares of Alnylam Pharmaceuticals worth $1.7B as of Q2 2026.
  • T. Rowe Price Investment Management bought 448,849 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $135M.
  • Alnylam Pharmaceuticals made up 1.11% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #16 holding.
  • T. Rowe Price Investment Management first reported a position in Alnylam Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • T. Rowe Price Investment Management's Alnylam Pharmaceuticals position peaked at $1.72B in Q1 2026.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.